A similar trend of high expression of CS1 (67.88%), NKp30 (65.44%), and NKp46 (57.79%) was observed in the CD56+ NK cells of very high-risk ALL subjects post-induction (2BD) chemotherapy as compared to healthy subjects (39.84%, 46.1%, and 49.9%, respectively), but it was not statistically significant (Figure 3D,H,J). This evidence concerns the gene NCR3 and acute lymphoblastic leukemia.